Article Excerpt:
TWST: What is Paladin Labs?Mr. Goodman: Paladin Labs is a rapidly growing specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceuticals for the Canadian market. We're now in our 11th year of business and we are proud to report that we are on track to record our 11th consecutive year of record revenues.
TWST: Give us some idea of what the product line looks like and how you've
developed it.
Mr. Goodman: We operate in the Canadian pharmaceutical market - a $14 billion
dollar market that has been characterized by high single, low double digit
growth over the past five years. In fact, Canada is the seventh largest
pharmaceutical market in the world.
We are continually on the lookout for innovative drugs in late-stage development
to commercialize in Canada. Paladin is well equipped to execute our strategy,
which involves acquiring innovative pharmaceuticals for the Canadian market. We
have $42 million of cash ($2.9X in cash per share), virtually no liabilities and
a healthy business that generated $9.4 million of EBITDA last year on $34
million of revenues ($0.63 in EBITDA per share).
Tickers included in this excerpt: PLB:TSX
TWST Newsletter
For more information call (212) 952 7433. The Wall Street Transcript does not endorse any of the comments made by interviewees, and does not make stock recommendations.